These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 27728892)
1. CYP2C19 genotyping combined with on-clopidogrel platelet reactivity in predicting major adverse cardiovascular events in Chinese patients with percutaneous coronary intervention. Tang XF; Han YL; Zhang JH; Wang J; Yao Y; He C; Xu B; Gao Z; Qiao SB; Chen J; Wu Y; Chen JL; Gao RL; Yang YJ; Yuan JQ Thromb Res; 2016 Nov; 147():108-114. PubMed ID: 27728892 [TBL] [Abstract][Full Text] [Related]
2. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617 [TBL] [Abstract][Full Text] [Related]
3. The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese patients. Tang N; Yin S; Sun Z; Xu X; Qin J Scand J Clin Lab Invest; 2015 May; 75(3):223-9. PubMed ID: 25594796 [TBL] [Abstract][Full Text] [Related]
4. Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study. Palmerini T; Calabrò P; Piscione F; De Servi S; Cattaneo M; Maffeo D; Toso A; Bartorelli A; Palmieri C; De Carlo M; Capodanno D; Barozzi C; Tomasi L; Della Riva D; Mariani A; Taglieri N; Reggiani LB; Bianchi R; De Rosa R; Mariani M; Podda G; Généreux P; Stone GW; Angiolillo DJ JACC Cardiovasc Interv; 2014 Oct; 7(10):1117-27. PubMed ID: 25240538 [TBL] [Abstract][Full Text] [Related]
5. Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis. Zhang L; Yang J; Zhu X; Wang X; Peng L; Li X; Cheng P; Yin T Thromb Res; 2015 Mar; 135(3):449-58. PubMed ID: 25511576 [TBL] [Abstract][Full Text] [Related]
6. [Impact of CYP2C19 genotype and platelet function on clinical outcome in coronary atherosclerotic heart diseases patients received clopidogrel post percutaneous coronary intervention]. Wu Y; Zhang XX; Tian L; Jiang JJ; Xu L; Huang YL; Liu H; Li YS Zhonghua Xin Xue Guan Bing Za Zhi; 2017 May; 45(5):377-385. PubMed ID: 28511321 [No Abstract] [Full Text] [Related]
7. Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel. Qiu LN; Sun Y; Wang L; Han RF; Xia XS; Liu J; Li X Eur J Pharmacol; 2015 Jan; 747():29-35. PubMed ID: 25489921 [TBL] [Abstract][Full Text] [Related]
8. Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance. Siasos G; Oikonomou E; Vavuranakis M; Kokkou E; Mourouzis K; Tsalamandris S; Zaromitidou M; Kioufis S; Tsigkou V; Deftereos S; Stefanadis C; Tousoulis D Cardiology; 2017; 137(2):104-113. PubMed ID: 28329746 [TBL] [Abstract][Full Text] [Related]
9. CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention. Liu T; Yin T; Li Y; Song LQ; Yu J; Si R; Zhang YM; He Y; Guo WY; Wang HC Coron Artery Dis; 2014 Aug; 25(5):412-20. PubMed ID: 24608794 [TBL] [Abstract][Full Text] [Related]
10. Association between high on-treatment platelet reactivity and occurrence of cerebral ischemic events in patients undergoing percutaneous coronary intervention. Komosa A; Siller-Matula JM; Lesiak M; Michalak M; Kowal J; Mączyński M; Siniawski A; Mularek-Kubzdela T; Wiśniewski S; Grajek S Thromb Res; 2016 Feb; 138():49-54. PubMed ID: 26826508 [TBL] [Abstract][Full Text] [Related]
11. [Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel]. Cano P; Consuegra-Sánchez L; Conesa P; Torres-Moreno D; Jaulent L; Dau D; Picó F; Villegas M Med Clin (Barc); 2014 Jul; 143(1):6-12. PubMed ID: 23850044 [TBL] [Abstract][Full Text] [Related]
12. Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention. Olędzki S; Kornacewicz-Jach Z; Safranow K; Kiedrowicz R; Gawrońska-Szklarz B; Jastrzębska M; Gorący J Eur J Clin Pharmacol; 2017 Sep; 73(9):1085-1094. PubMed ID: 28589365 [TBL] [Abstract][Full Text] [Related]
13. High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers. Marcucci R; Giusti B; Paniccia R; Gori AM; Saracini C; Valente S; Giglioli C; Parodi G; Antoniucci D; Gensini GF; Abbate R Platelets; 2012; 23(8):586-93. PubMed ID: 22390861 [TBL] [Abstract][Full Text] [Related]
14. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. Harmsze A; van Werkum JW; Bouman HJ; Ruven HJ; Breet NJ; Ten Berg JM; Hackeng CM; Tjoeng MM; Klungel OH; de Boer A; Deneer VH Pharmacogenet Genomics; 2010 Jan; 20(1):18-25. PubMed ID: 19934793 [TBL] [Abstract][Full Text] [Related]
15. Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study. Collet JP; Hulot JS; Cuisset T; Rangé G; Cayla G; Van Belle E; Elhadad S; Rousseau H; Sabouret P; O'Connor SA; Abtan J; Kerneis M; Saint-Etienne C; Barthélémy O; Beygui F; Silvain J; Vicaut E; Montalescot G; Eur J Clin Pharmacol; 2015 Nov; 71(11):1315-24. PubMed ID: 26265231 [TBL] [Abstract][Full Text] [Related]
16. Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease. Guo B; Tan Q; Guo D; Shi Z; Zhang C; Guo W J Vasc Surg; 2014 Oct; 60(4):993-1001. PubMed ID: 24877854 [TBL] [Abstract][Full Text] [Related]
17. Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients. Zhang L; Chen Y; Jin Y; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Li X; Li Y; Zhang Y; Lu C; Yin T Thromb Res; 2013 Jul; 132(1):81-7. PubMed ID: 23726091 [TBL] [Abstract][Full Text] [Related]
18. Association of CYP2C19 genotype with periprocedural myocardial infarction after uneventful stent implantation in Chinese patients receiving clopidogrel pretreatment. Wu H; Qian J; Sun A; Wang Q; Ge J Circ J; 2012; 76(12):2773-8. PubMed ID: 22971905 [TBL] [Abstract][Full Text] [Related]
19. Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects. Mao L; Jian C; Changzhi L; Dan H; Suihua H; Wenyi T; Wei W Arch Cardiovasc Dis; 2013 Oct; 106(10):517-27. PubMed ID: 24080325 [TBL] [Abstract][Full Text] [Related]
20. Intrinsic platelet reactivity before start with clopidogrel as predictor for on-clopidogrel platelet function and long-term clinical outcome. Hochholzer W; Valina CM; Bömicke T; Amann M; Stratz C; Nührenberg T; Trenk D; Neumann FJ Thromb Haemost; 2015 Jul; 114(1):109-14. PubMed ID: 25832119 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]